Navigation Links
Copying mother nature's designs
Date:12/10/2009

RIVERSIDE, Calif. David Bocian of the University of California, Riverside will receive more than $1 million over five years as a co-investigator in the Photosynthetic Antenna Research Center (PARC), to be headquartered at Washington University in St. Louis, Mo. The center seeks to better understand natural photosynthetic systems and design more durable human-made compounds for capturing light.

"Research on solar cells during the past 15 years has failed to appreciably increase cell efficiency," said Bocian, a professor of biophysical and materials chemistry, who researches energy conversion systems using a range of analytical techniques. Bocian cites lack of funding for basic research as the reason why today's solar cells have only 6-11 percent energy efficiency.

But there is hope in Congress's recent approval of funding for PARC and 45 similar Energy Frontier Research Centers (EFRCs) through the Department of Energy.

"The precedent in this case is the number of centers funded," Bocian said. "Normally the National Science Foundation calls for proposals and eventually funds three or four centers."

The $277 million allocated for the 46 EFRCs is significant, especially in that it requires no "deliverables" (functioning products) but rather seeks to address basic science questions.

Shiny silicon-wafer cells are extremely brittle, but Bocian explained that the new solar cells would be flexible, and could be integrated with textiles, allowing clothes to act as a walking power source for cell phones and computers.

He hopes to aid the development of what he calls "bio-inspired" antenna systems, which will collect and focus light to power solar cells.

These systems are bio-inspired because they are based on t
'/>"/>

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Scientists are first to observe the global motions of an enzyme copying DNA
2. A year after discovery, Congos mother lode of gorillas remains vulnerable
3. Playing sport up to the end of pregnancy is healthy for the baby and the mother
4. Faithful mothers have healthier babies
5. Duke develops nano-scale drug delivery for chemotherapy
6. Female choice benefits mothers more than offspring
7. Checkered history of mother and daughter cells explains cell cycle differences
8. Natural compounds, chemotherapeutic drugs may become partners in cancer therapy
9. Mothers immune system may block fetal treatments for blood diseases
10. Common chemotherapy drug triggers fatal allergic reactions
11. New book suggests Earth perhaps not such a benevolent mother after all
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Copying mother nature's designs
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... a new model to predict the impact of climate change ... Australia information that could help limit its spread. ... of the British Ecological Society,s journal Functional Ecology , ... and expand the mosquito,s range. But human behaviour in ...
... Institute at Arizona State University associate research scientist Melha Mellata, ... USDA funded project to develop a vaccine against a leading ... APEC is part of a large, diverse group ... They cause a number of complex brain, lung and urinary ...
... January 2009. The Alfred Wegener Institute for Polar ... conduct the ongoing Polarstern expedition LOHAFEX". Independent scientific ... of Education and Research and the Federal Ministry ... concluded that the iron fertilisation experiment LOHAFEX is ...
Cached Biology News:Hoarding rainwater could 'dramatically' expand range of dengue-fever mosquito 2New insights into a leading poultry disease and its risks to human health 2New insights into a leading poultry disease and its risks to human health 3New insights into a leading poultry disease and its risks to human health 4Polarstern expedition 'LOHAFEX' can be conducted 2Polarstern expedition 'LOHAFEX' can be conducted 3
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
(Date:6/1/2015)... ON , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... period ended March 31, 2015.  Biorem,s complete 2015 first quarter financial ... Financial Summary:Three-months ended March 31,(in CDN$,000 except ... , 4,689 , 1,974 Gross profit , ... (318) Net earnings (loss) , 528 , ...
(Date:6/1/2015)... , June 1, 2015  The Val Skinner ... national innovative science curriculum for high school students focused ... 16 th annual LIFE Event (LPGA Pros in ... Ridge Country Club in West Caldwell, N.J. ... LPGA,s biggest stars raised more than $500,000 on Monday, ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, ... of positive interim results from a poster presented ... open label randomised phase III trial of the ... in patients receiving cisplatin (Cis) monotherapy for standard ... the American Society of Clinical Oncology (ASCO) 2015 ...
Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Val Skinner Foundation Announces Partnership With Discovery Education 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... 2008, Abbott,s,( NYSE: ABT ) employee giving in the ... number of participating employees and total dollar contributions,despite difficult ... Abbott,employees (74 percent) participated in the company,s employee giving ... contributed more than $12.6,million to non-profit groups in 2008, ...
... Offering , ... Rochester, New York ... innovator in advanced cardiac safety biomakers and automated QT analysis, ... as its quarter over quarter revenues have grown in excess ...
... Belgium and LUND, Sweden, February 23 , ... of Partial Factor VIII Inhibition in,Patients Undergoing Knee Replacement ... Brussels: THR) and co-development partner,BioInvent International (OMXS: BINV) announce ... Phase II trial with their long-acting anticoagulant,TB-402 for the ...
Cached Biology Technology:Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 2Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 3iCardiac Reports Significant Revenue Growth and Profitability 2iCardiac Reports Significant Revenue Growth and Profitability 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 2ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 4ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 5
Protein Tyrosine Phosphatase Sampler Kit 10g each...
Zonula Adherens Sampler Kit 10 mu g each...
Golgi Sampler Kit 10g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Biology Products: